NCT06466850 Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
| NCT ID | NCT06466850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Isfahan University of Medical Sciences |
| Condition | Osteoarthritis, Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA). OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS). MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA. Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity. This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.
Eligibility Criteria
Inclusion Criteria: * Chronic history (for at least 3 months) of knee joint pain * Body mass index (BMI) between 21.5 and 29.5 * Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale) Exclusion Criteria: * Rheumatoid arthritis and other rheumatic diseases * Varus or valgus more than 10 degrees; lateral subluxation of the patella * Deformity at the joint levels or adjacent to the knee due to fracture or any other injury * Complete rupture of the ligament and meniscus leading to laxity or locking * Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk * Hyaluronic acid infiltration within the previous six months * Hemoglobin levels \<10 g/dL;
Contact & Investigator
Leila Dehghani, Dr
PRINCIPAL INVESTIGATOR
Isfahan University of Medical Sciences
Frequently Asked Questions
Who can join the NCT06466850 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Osteoarthritis, Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06466850 currently recruiting?
Yes, NCT06466850 is actively recruiting participants. Contact the research team at l_dehghani2002@yahoo.com for enrollment information.
Where is the NCT06466850 trial being conducted?
This trial is being conducted at Isfahan, Iran.
Who is sponsoring the NCT06466850 clinical trial?
NCT06466850 is sponsored by Isfahan University of Medical Sciences. The principal investigator is Leila Dehghani, Dr at Isfahan University of Medical Sciences. The trial plans to enroll 20 participants.